New York and London – January 9, 2023 – Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.
The acquisition will further maximize the value of Amryt’s current portfolio and accelerate its ability to reach more patients in need globally. The total upfront consideration implied by the transaction at close is approximately $1.25 billion, with the CVRs representing an additional $225 million of potential consideration.
Amryt is a global company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. The company comprises a strong and growing portfolio of commercial and development assets.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.